Quick Answer
Cogent Biosciences, Inc. reported Research And Development Expense of $269.78 million for the year ending 2025.
- Cogent Biosciences, Inc. showed an increase of +16.0% in Research And Development Expense from 2024 to 2025.
- This data is from Cogent Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $6.95 million | Q2 2017: $7.14 million | Q3 2017: $8.18 million | Q1 2018: $8.14 million | Q2 2018: $9.13 million | Q3 2018: $10.25 million | Q1 2019: $12.40 million | Q2 2019: $10.62 million | Q3 2019: $10.34 million | Q1 2020: $9.50 million | Q2 2020: $5.13 million | Q3 2020: $5.00 million | Q1 2021: $8.21 million | Q2 2021: $12.39 million | Q3 2021: $14.80 million | Q1 2022: $25.47 million | Q2 2022: $29.48 million | Q3 2022: $29.94 million | Q1 2023: $36.04 million | Q2 2023: $38.87 million | Q3 2023: $50.13 million | Q1 2024: $52.71 million | Q2 2024: $54.29 million | Q3 2024: $63.61 million | Q1 2025: $63.03 million | Q2 2025: $62.20 million | Q3 2025: $68.99 million.
- Over the full 9 years of available data (2017 to 2025), Cogent Biosciences, Inc.'s Research And Development Expense has grown by 804.3%.
- Historical annual values: Fiscal year 2025: $269.78 million | Fiscal year 2024: $232.66 million | Fiscal year 2023: $173.76 million | Fiscal year 2022: $121.63 million | Fiscal year 2021: $55.91 million | Fiscal year 2020: $25.74 million | Fiscal year 2019: $43.71 million | Fiscal year 2018: $38.29 million | Fiscal year 2017: $29.83 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: